Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

WATERTOWN, Mass., Aug. 03, 2023 -- Eloxx Pharmaceuticals, Inc. , a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it received notice from the Nasdaq...

Related Keywords

John Woolford ,Laureen Cassidy ,Sumit Aggarwal ,Nasdaq Listing Qualifications Panel The Hearings ,Nasdaq Stock Market ,Eloxx Pharmaceuticals Inc ,Nasdaq Hearings Panel ,Nasdaq ,Globenewswire Inc ,Eloxx Pharmaceuticals ,Hearings Panel ,Listing Qualifications Panel ,Listing Rule ,Nasdaq Capital Market ,Market Value ,Nasdaq Capital ,Ribosome Modulating Agents ,Eukaryotic Ribosome Selective Glycosides ,Private Securities Litigation Reform Act ,Quarterly Report ,Markets ,